Login
$CABA
$1.12 +$0.01 (0.9%) After hours

$CABA 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d...

05 Nov 2026 8-K: Results of Operations and Financial Condition

RESET-Myositis® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data

14 Sep 2026 8-K: Other Events

In connection with Cabaletta Bio’s (the “Corporation”) June 2025 underwritten public offering, the Corporation issued 53,090,190 common stock warrants (the “Common Stock Warrants”) that had an exercise price of $2.50 per whole share of i...

13 Aug 2026 8-K: Results of Operations and Financial Condition

Registrational RESET-Myositis® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

11 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Cabaletta Bio, Inc. (the “Corporation”), a corporation duly organized and existing under the laws of the State of Delaware pursuant to Section 242 of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as ...

03 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d...

14 May 2026 8-K: Results of Operations and Financial Condition

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

14 May 2026 8-K: Regulation FD Disclosure; Other Events

Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d...

04 May 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

1. INTRODUCTORY. Cabaletta Bio, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Underwrite...

04 May 2026 8-K: Other Events

Cabaletta intends to present new clinical and translational data from 4 refractory patients that received rese-cel at the lowest dose without preconditioning in the RESET-PV® (pemphigus vulgaris) trial at the American Society of Gene & C...

20 Apr 2026 8-K: Other Events

Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d...

23 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

12 Jan 2026 8-K: Regulation FD Disclosure; Other Events

Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d...

10 Nov 2025 8-K: Results of Operations and Financial Condition

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

29 Oct 2025 8-K: Other Events

Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d...

27 Oct 2025 8-K: Regulation FD Disclosure; Other Events

Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d...

09 Oct 2025 8-K: Regulation FD Disclosure; Other Events

Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d...

03 Sep 2025 8-K: Regulation FD Disclosure

Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any d...

07 Aug 2025 8-K: Results of Operations and Financial Condition

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

12 Jun 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Introductory. Cabaletta Bio, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of (i) 39,200,000 shares (the “Shares”) of its common...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support